Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stefenac
- Development stage
- Unknown
- Lead developer
- Stevia Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Stefenac is a brand of analgesic and anti-inflammatory medications developed and marketed by Stevia Pharmaceuticals. The product line consists of several fixed-dose combination oral tablets primarily based on the active ingredient aceclofenac, a non-steroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class. Stefenac is utilized for the management of pain and inflammation associated with conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. The range includes Stefenac-P (aceclofenac combined with paracetamol), Stefenac-SP (aceclofenac and paracetamol with the proteolytic enzyme serratiopeptidase), and Stefenac-MR (aceclofenac and paracetamol with the skeletal muscle relaxant chlorzoxazone). These formulations are designed to provide synergistic effects for treating complex musculoskeletal pain, inflammation, and muscle spasms.
- Brand names
- StefenacStefenac-PStefenac-SPStefenac-MR
- Other names
- StefenacStefenac-PStefenac-SPStefenac-MR
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Stefenac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stefenac.